Crossmark

Artificial intelligence for immunotherapy response assessment in lung cancer using PET/CT reports

Crossref DOI link: https://doi.org/10.1007/s11604-025-01840-3

Published Online: 2025-10-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ismayilov, Rashad https://orcid.org/0000-0002-7093-2722
Altundag, Ozden https://orcid.org/0000-0003-0197-6622
Gencoglu, Esra Arzu https://orcid.org/0000-0003-4631-1683
Aktas, Ayse https://orcid.org/0000-0003-0149-2265
Alparslan, Sila https://orcid.org/0009-0005-5702-7049
Ozcicek, Asli https://orcid.org/0009-0001-4392-7880
Turhanoglu, Doga https://orcid.org/0000-0002-5967-5892
Oguz, Arzu https://orcid.org/0000-0001-6512-6534
Farzaliyeva, Aydan https://orcid.org/0000-0001-8504-4798
Ramazanoglu, Mehmet Nezir https://orcid.org/0009-0007-4976-182X
Kocak, Murat https://orcid.org/0000-0001-6510-3666
Akcali, Zafer https://orcid.org/0000-0003-2473-4431
License Information

Text and Data Mining valid from 2025-10-15

Version of Record valid from 2025-10-15
More Information

Article History

Received: 12 May 2025

Accepted: 10 July 2025

First Online: 15 October 2025

Declarations

:

: The authors declare that they have no conflict of interest.

: This study was approved by Baskent University Institutional Review Board with a waiver for documented informed consent from patients (project no: KA25/148).